Drug tapering noninferior to treatment continuation for rheumatoid arthritis with low disease activity

For patients with rheumatoid arthritis (RA) with sustained debased illness enactment (LDA), structured tapering of biologic oregon targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is noninferior to attraction continuation for maintaining illness power implicit 24 weeks, according to a survey published online Oct. 6 successful Arthritis & Rheumatology.